Women in abdominal compared to femoral adiposity phenotypes have been suggested to have a hormonal pattern that is associated with increased risk of breast cancer. Studies of endogenous sex hormone levels and body fat phenotypes are limited in Caucasian women, and even more so in African-American (AA) women. AA women are to have higher prevelances of obesity and abdominal adiposity, and have a higher premenopausal breast cancer rate than Caucasian women. Using a cross-sectional study desing, this study aims to determine the relationship between serum sex hormones levels and body fat phenotypes in premenopausal AA women. Only eligible AA women with abdominal adiposity defined as a waist to hip ratio (whr) of >0.85, and femoral adiposity with a whr=,0.75 will be recruited into the study to ensure that we will have sufficient numbers within each adiposity phenotype to test our specific aims. Serum levels of total estrone, estrone sulfate, estradiol, free estradiol, androstenedione, testosterone, and free testosterone, as well as sex hormone binding globulin, will be measured on two consecutive mornings during the follicular phase of the menstrual cycle (days 4-7). Body fat phenotype will be determined by anthropometry, and using a total body Dual Energy X- ray Absortiometry (DEXA) scanner. Percent body fat wil be determined using skinfold measurements, total body dexa scanner, and the bioelectrical impedance analysis (BIA) method. This study will provide important data in the possible identification of body fat phenotype as a marker of hormonal pattern associated with increased risk in the developement of breast cancer in premenopausal AA women.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
2M01RR000054-36A1
Application #
6245542
Study Section
Project Start
1997-05-01
Project End
1997-11-30
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
36
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Tufts University
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02111
Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Lamon-Fava, Stefania; Diffenderfer, Margaret R; Barrett, P Hugh R et al. (2018) Differential Effects of Estrogen and Progestin on Apolipoprotein B100 and B48 Kinetics in Postmenopausal Women. Lipids 53:167-175
Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201
Dad, Taimur; Abebe, Kaleab Z; Bae, K Ty et al. (2018) Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep 3:619-624
Brosnahan, Godela M; Abebe, Kaleab Z; Rahbari-Oskoui, Frederic F et al. (2017) Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev 13:109-120
Di Fiore, Juliann M; Martin, Richard J; Li, Hong et al. (2017) Patterns of Oxygenation, Mortality, and Growth Status in the Surfactant Positive Pressure and Oxygen Trial Cohort. J Pediatr 186:49-56.e1
Scherzer, Rebecca; Heymsfield, Steven B; Rimland, David et al. (2017) Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV monoinfection. AIDS 31:71-79
Torres, Vicente E; Abebe, Kaleab Z; Schrier, Robert W et al. (2017) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 91:493-500
Younge, Noelle; Goldstein, Ricki F; Bann, Carla M et al. (2017) Survival and Neurodevelopmental Outcomes among Periviable Infants. N Engl J Med 376:617-628
Irazabal, María V; Abebe, Kaleab Z; Bae, Kyongtae Ty et al. (2017) Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant 32:1857-1865

Showing the most recent 10 out of 412 publications